Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2022 Jul;82(11):1229-1234. doi: 10.1007/s40265-022-01749-5.
Mosunetuzumab (Lunsumio), an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma. Mosunetuzumab was recently conditionally approved in the EU for the treatment of relapsed or refractory follicular lymphoma in adults who have received at least two prior systemic therapies. This article summarizes the milestones in the development of mosunetuzumab leading to this first approval for relapsed or refractory follicular lymphoma.
莫努匹韦（Lunsumio），一种抗 CD20/CD3 T 细胞双特异性抗体，由罗氏开发用于治疗复发或难治性滤泡性淋巴瘤。莫努匹韦最近在欧盟有条件批准用于治疗至少接受过两次全身治疗的成人复发或难治性滤泡性淋巴瘤。本文总结了导致莫努匹韦首次批准用于复发或难治性滤泡性淋巴瘤的开发里程碑。
